Show simple item record

dc.date.accessioned2022-06-24T16:16:56Z
dc.date.available2022-06-24T16:16:56Z
dc.date.issued2022-06-28
dc.identifier.citationPan American Health Organization. Guideline for the treatment of leishmaniasis in the Americas. Second edition. Washington, DC: PAHO; 2022. Available from: https://doi.org/10.37774/9789275125038.en_US
dc.identifier.isbn978-92-75-12504-5 (print version)
dc.identifier.isbn978-92-75-12503-8 (PDF)
dc.identifier.urihttps://iris.paho.org/handle/10665.2/56120
dc.description.abstractLeishmaniases are neglected infectious diseases of great importance in the Americas because of their morbidity, mortality, and wide geographical distribution. Out of the three main clinical forms of leishmaniasis, cutaneous leishmaniasis is the most common and the visceral form is the most severe, causing death in up to 90% of untreated people. In 2013, the Pan American Health Organization (PAHO) developed recommendations for the treatment of leishmaniases in the Americas using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. However, given the new evidence that has accumulated since that time, there was a need to revise those recommendations. This second edition presents updated therapeutic recommendations for leishmaniases, detailing the treatment indications, criteria and schemes in the regional context. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional. For miltefosine, there is strong evidence against its usage in patients with leishmaniasis caused by Leishmania infantum. Further important changes include the division of recommendations by adult and pediatric populations, the addition of Leishmania species, and for immunocompromised patients, a strong recommendation against the use of pentavalent antimonials.en_US
dc.language.isoenen_US
dc.publisherPAHOen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 IGO*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/igo/*
dc.subjectLeishmaniasisen_US
dc.subjectLeishmaniasis, Visceralen_US
dc.subjectLeishmaniasis, Mucocutaneousen_US
dc.subjectLeishmaniasis, Cutaneousen_US
dc.subjectNeglected Diseasesen_US
dc.subjectInfectious Diseaseen_US
dc.subjectAmericasen_US
dc.titleGuideline for the Treatment of Leishmaniasis in the Americas. Second Editionen_US
dc.typeProcedures, manuals, guidelinesen_US
dc.rights.holderPan American Health Organizationen_US
dc.contributor.corporatenamePan American Health Organizationen_US
dc.description.notesThis second edition is a revised version of the previous publication Leishmaniasis in the Americas. Recommendations for the Treatment: https://iris.paho.org/handle/10665.2/7704en_US
paho.isfeatured0en_US
paho.publisher.countryUnited Statesen_US
paho.publisher.cityWashington, D.C.en_US
dc.identifier.doihttps://doi.org/10.37774/9789275125038
paho.source.centercodeUS1.1en_US
paho.relation.languageVersion10665.2/56121
paho.contributor.departmentCommunicable Diseases and Environmental Determinants of Health (CDE)en_US
paho.iswhotranslationNoen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO